Pharma Frontiers: Pfizer's 2024 Outlook and AstraZeneca's Strategic Acquisition

Pharma Frontiers: Pfizer's 2024 Outlook and AstraZeneca's Strategic Acquisition In this episode of Top daily news, hosted by Burt , we dive into the latest developments in the pharmaceutical industry, highlighting key moves by Pfizer and AstraZeneca. We'll examine Pfizer's weaker-than-expected guidance for 2024, driven by reduced demand for its COVID-19 products, and discuss the potential impact on the company and the industry. Additionally, we explore AstraZeneca's acquisition of vaccine company Icosavax, valued at $1.1 billion, and its implications for the vaccine market, particularly with the promising IVX-A12 vaccine candidate. Tune in to "Pharma Frontiers: Pfizer's 2024 Outlook and AstraZeneca's Strategic Acquisition" for an insightful analysis of these significant industry shifts. Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices